The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Starboard said a former CEO and CFO had assisted in its activist campaign but then were pressured to express support for the ...

Some misleading narratives about Bourla’s leadership that have been put forward have been distinctly unfair,' write Jeff ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Starboard Value has asked Pfizer to set up a special committee to investigate allegations that two of its former senior ...

Investors shrugged as Illumina pressed its case for building on its longtime leadership in next-generation sequencing, ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer (NYSE: PFE) ...

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current ...